Skip to main content
. 2017 Apr 5;12(4):e0175021. doi: 10.1371/journal.pone.0175021

Table 1. Characteristics of identified studies.

Key results/Findings (psychometric properties)
Author (s) Country Year Sample Size Source PWB α EWB α FGWB α SWB α CF α FAHI Established Sensitivity
Total α validity to change
Byrne S. & Petry N. [30] USA 2012 n = 170 Single 0.85 0.89 0.82 0.70 0.70 0.92 Convergent YES
Discriminant
Peterman A.H. et al [22] USA 1997 n = 361 BIOQoL (n = 110) } Divergent YES
VCU data (n = 39) 0.91 0.82 0.86 0.73 0.75 0.91 Construct
Multi-center trial (n = 212)
Viala-Danten M. et al [13] USA 2010 n = 1661 POWER trial (n = 565) 0.91 0.83 0.89 0.85 0.75 NR Construct NR
DUET trial (n = 1,091*) 0.92 0.84 0.89 0.84 0.72 NR
Cella D.F. et al [17] USA 1996 n = 245 Stress sample (n = 110) } 0.91 Concurrent YES
BIOQoL English (n = 71) NR NR NR NR NR 0.91
BIOQoL Spanish (n = 64) 0.92
Feinberg J. et al [34] USA, Canada 2011 n = 429 Single NR NR NR NR NR NR NR NR
& Puerto Rico
Earthman C.P. [33] USA 2002 n = 25 Single 0.91 (7 Item) NR NR NR NR NR NR NR
Hasanah C.I., Zaliha A.R., Malaysia 2010 n = 271 Single NR NR NR NR NR NR NR NR
Mahiran M. [23]
Cianfrocca M. et al [35] USA 2010 n = 73 Single NR NR NR NR NR NR NR NR
Rao D. et al [24] Continental 2007 n = 273 Single NR NR NR NR NR NR NR NR
United States
& Puerto rico
Abrams D.I, Steinhart C., USA 2000 n = 221 Single NR NR NR NR NR NR NR NR
Frascino R. [36]
Tomita A et al [31] South Africa 2013 n = 160 Single 0.88 0.83 0.85 0.72 0.65 0.86 NR NR
Tomita A et al [37] South Africa 2014 n = 51 Single 0.92 0.80 0.83 0.73 0.60 0.90 NR NR
Diamond C., USA 2010 n = 100 Single NR NR NR NR NR NR NR NR
Taylor T.H.,
Anton-Culver H. [38]
Cella D.F. et al [39] USA 2010 n = 1203 DUET– 1 (n = 612) NR NR NR NR NR NR NR NR
DUET– 2 (n = 591)
Sikkema K.J. et al [40] USA 2005 n = 235 Single NR NR NR NR NR NR NR NR
Winston A. [41] Multi- centered 2010 n = 256 Single NR NR NR NR NR NR NR NR

BIOQoL-Bilingual Intercultural Oncology Quality of Life, VCU -Virginia Commonwealth University, FAHI–Functional Assessment of HIV infection, PWB–Physical Wellbeing, EWB–Emotional Wellbeing, FWB–Functional and Global Wellbeing, SWB–Social Wellbeing, CF–Cognitive Functioning, POWER–Performance Of TMC114/r When evaluated in treatment-Experienced patients with protease inhibitor Resistance. DUET- a randomized, double-blind, placebo-controlled, phase III trial examining the efficacy, tolerability, and safety of TMC125 in treatment-experienced patients. NR–Not Reported

* Number of patients with all sub scale scores available